Anti TROP2 antibody drug conjugate - Peak Bio
Alternative Names: Anti TROP2 ADC - Peak Bio; Torpedo™; Trop2 PH1 ADC - Peak BioLatest Information Update: 21 Sep 2023
At a glance
- Originator Peak Bio
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Sep 2023 Anti TROP2 antibody drug conjugate - Peak Bio is available for licensing as of 19 Sep 2023. www.peak-bio.com
- 19 Sep 2023 Peak Bio files for provisional patent application for Anti TROP2 antibody drug conjugate
- 14 Apr 2023 Pharmacodynamics and adverse events data from a preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)